このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

GC Biopharma バランスシートの健全性

財務の健全性基準チェック /26

GC Biopharmaの総株主資本は₩1,494.2B 、総負債は₩693.8Bで、負債比率は46.4%となります。総資産と総負債はそれぞれ₩2,685.0Bと₩1,190.8Bです。 GC Biopharmaの EBIT は₩32.5Bで、利息カバレッジ比率1.1です。現金および短期投資は₩64.8Bです。

主要情報

46.4%

負債資本比率

₩693.80b

負債

インタレスト・カバレッジ・レシオ	1.1x
現金	₩64.79b
エクイティ	₩1.49t
負債合計	₩1.19t
総資産	₩2.68t

財務の健全性に関する最新情報

Recent updates

Is GC Biopharma (KRX:006280) A Risky Investment?

May 25

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

財務状況分析

短期負債: A006280の短期資産 ( ₩1,107.0B ) が短期負債 ( ₩803.8B ) を超えています。

長期負債: A006280の短期資産 ( ₩1,107.0B ) が長期負債 ( ₩387.0B ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: A006280の純負債対資本比率 ( 42.1% ) は高いと見なされます。

負債の削減: A006280の負債対資本比率は、過去 5 年間で32.7%から46.4%に増加しました。

債務返済能力: A006280の営業キャッシュフローはマイナスであるため、負債は十分にカバーされていません。

インタレストカバレッジ: A006280の負債に対する利息支払いは EBIT ( 1.1 x coverage) によって十分にカバーされていません。

GC Biopharma バランスシートの健全性

財務の健全性 基準チェック /26

主要情報

財務の健全性に関する最新情報

Is GC Biopharma (KRX:006280) A Risky Investment?

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Recent updates

New major risk - Financial position

Is GC Biopharma (KRX:006280) A Risky Investment?

Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Upcoming dividend of ₩1,750 per share at 1.4% yield

GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Consensus EPS estimates fall from profit to ₩269 loss

GC Biopharma Applies for MFDS Approval

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 18%, revenue downgraded

GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 11%

GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to ₩176,750

Upcoming dividend of ₩2,000 per share

Price target decreased to ₩191,222

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to ₩208,875

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased to ₩254,400

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Investor sentiment improved over the past week

Price target decreased to ₩310,167

Consensus forecasts updated

Upcoming dividend of ₩1,500 per share

Price target decreased to ₩418,333

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

Price target increased to ₩434,000

Price target increased to ₩383,000

First quarter 2021 earnings released: EPS ₩1,293 (vs ₩368 loss in 1Q 2020)

US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩7,087 (vs ₩118 in FY 2019)

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

New 90-day low: ₩333,500

GC Pharma Finalises Agreement with Moderna and the Government of the Republic of Korea for Covid-19 Vaccines Distribution

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross Corporation, Annual General Meeting, Mar 25, 2021

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

New 90-day high: ₩505,000

GC Pharma and Clinigen K.K. Announces Marketing Approval for Hunterase ICV Injection 15 mg

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

New 90-day high: ₩475,000

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Upcoming Dividend of ₩1,000 Per Share

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Analysts update estimates

New 90-day high: ₩378,000

Analysts update estimates

Price target raised to ₩198,111

Grifols, S.A. (BME:GRF) completed the acquisition of Plasma Fractionation Facility in Montreal and Plasma Collection Centers in US from Green Cross Corporation (KOSE:A006280).

New 90-day high - ₩239,000

Price target raised to ₩168,250

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /26